BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
33.79
-0.32 (-0.94%)
At close: Jan 17, 2025, 4:00 PM
34.68
+0.89 (2.63%)
After-hours: Jan 17, 2025, 4:30 PM EST
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 48.33, with a low estimate of 37 and a high estimate of 70. The average target predicts an increase of 43.03% from the current stock price of 33.79.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BBIO stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 3 | 4 | 6 | 6 | 6 | 6 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $45 → $50 | Buy | Maintains | $45 → $50 | +47.97% | Dec 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $49 | Strong Buy | Reiterates | $49 | +45.01% | Dec 16, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $45 → $48 | Buy | Maintains | $45 → $48 | +42.05% | Nov 25, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $42 → $45 | Strong Buy | Maintains | $42 → $45 | +33.18% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $43 → $49 | Strong Buy | Maintains | $43 → $49 | +45.01% | Nov 25, 2024 |
Financial Forecast
Revenue This Year
224.14M
from 9.30M
Increased by 2,309.33%
Revenue Next Year
182.34M
from 224.14M
Decreased by -18.65%
EPS This Year
-2.67
from -3.95
EPS Next Year
-3.77
from -2.67
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 244.2M | 360.2M | 678.3M | |||
| Avg | 224.1M | 182.3M | 421.4M | |||
| Low | 211.7M | 55.8M | 209.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2,524.4% | 60.7% | 272.0% | |||
| Avg | 2,309.3% | -18.6% | 131.1% | |||
| Low | 2,175.4% | -75.1% | 14.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.47 | -2.65 | -1.80 | |||
| Avg | -2.67 | -3.77 | -2.92 | |||
| Low | -2.95 | -4.42 | -3.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.